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Agents that remodel the tumor microenvironment (TME), prime
functional tumor-specific T cells, and block inhibitory signaling
pathways are essential components of effective immunotherapy.
We are evaluating live-attenuated, double-deleted Listeria mono-
cytogenes expressing tumor antigens (LADD-Ag) in the clinic. Here
we show in numerous mouse models that while treatment with
nonrecombinant LADD induced some changes in the TME, no an-
titumor efficacy was observed, even when combined with immune
checkpoint blockade. In contrast, LADD-Ag promoted tumor rejec-
tion by priming tumor-specific KLRG1+PD1loCD62L− CD8+ T cells. These
IFNγ-producing effector CD8+ T cells infiltrated the tumor and con-
verted the tumor from an immunosuppressive to an inflamed microen-
vironment that was characterized by a decrease in regulatory T cells
(Treg) levels, a proinflammatory cytokine milieu, and the shift of M2
macrophages to an inducible nitric oxide synthase (iNOS)+CD206− M1
phenotype. Remarkably, these LADD-Ag–induced tumor-specific T cells
persisted for more than 2 months after primary tumor challenge and
rapidly controlled secondary tumor challenge. Our results indicate that
the striking antitumor efficacy observed in mice with LADD-based im-
munotherapy stems from TME remodeling which is a direct conse-
quence of eliciting potent, systemic tumor-specific CD8+ T cells.
Listeria monocytogenes | CD8+ T | tumor microenvironment |
cancer vaccine
Under immunosuppressive tumor microenvironment (TME)conditions, tumor-specific T cells rapidly become exhausted
(1). These dysfunctional T cells express high levels of inhibitory
receptors (e.g., PD1, LAG3) and are impaired in their ability to
produce cytokines such as TNFα and IFNγ (2). Suppressive
leukocyte populations in the TME that inhibit T cell function
include regulatory T cells (Tregs), myeloid-derived suppressor
cells (MDSCs), and tumor-associated macrophages (TAMs) (1).
TAMs have distinct functional types ranging from classically
activated macrophages (M1) associated with acute inflammation
and functional T cell immunity, to immunosuppressive macro-
phages (M2) associated with promoting tumor proliferation (3). Of
those genes that define M2 macrophages, arginase 1 (Arg1) and
mannose receptor (CD206) led to the concept of alternative activa-
tion of macrophages (4). IFNγ—known originally as a macrophage
activating factor—plays a major role in skewing macrophages toward
an M1 phenotype (5). Activated M1 macrophages respond with an
oxidative burst via inducible nitric oxide synthase (iNOS), and directly
kill tumor cells as well as produce cytokines that promote antitumor
immunity (3). Multiple strategies are being developed to overcome
immunosuppression to induce effective antitumor immunity (6).
One approach being evaluated clinically to induce antitumor
immunity is antigen-expressing viruses and intracellular bacteria
(7, 8). Upon challenge with intracellular microorganisms such as
Listeria monocytogenes (Lm), the immune system rapidly mounts an
innate inflammatory response characterized by MCP-1, IL-12p70,
and IFNγ production which promotes priming of pathogen-specific
T cell immunity (9). These Ag-specific CD8+ T cells express several
receptors including the killer cell lectin-like receptor G1 (KLRG1),
which has been used as a surrogate marker for terminally differentiated
short-lived effector CD8+ T cells (10). However, a recent study showed
that a population of CD8+ T cells bearing markers associated with
effector cells (KLRG1hiCD27loT-bethiEomeslo) persisted to the mem-
ory phase and provided optimal control of wild-type (WT) Lm (11).
We are evaluating a live-attenuated Lm immunotherapy plat-
form that lacks two virulence genes, the actin assembly-inducing
protein (actA) and internalin B (inlB); Lm ΔactA/ΔinlB (LADD,
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live-attenuated double-deleted Lm). actA deletion prevents cell-to-
cell spread and renders bacteria avirulent in a mouse listeriosis
model (12). inlB deletion blocks infection via the hepatocyte growth
factor receptor (13). LADD is rapidly cleared in mice without sig-
nificant hepatocyte damage following i.v. administration, and
is >1,000-fold attenuated relative toWT Lm (14). The immunologic
potency of LADD is equivalent to WT Lm. Several LADD-based
strains have been administered to more than 400 subjects, in mul-
tiple clinical studies in patients with advanced malignancies. Here,
we sought to understand how treatment of tumor-bearing mice with
LADD affects the TME, and hypothesized that antitumor efficacy
of LADD-Ag was due to both tumor-specific CD8+ T cell immunity
and TME modulation by this population.
Results
LADD-Ag Administration Inhibits Tumor Growth in a CD8+ T Cell-
Dependent Manner. To test efficacy and dissect the mechanism
of action of antitumor responses, we constructed a LADD strain
that expresses AH1 (LADD-AH1). AH1 is a dominant H-2Ld-re-
stricted CD8+ T cell epitope derived from endogenous retroviral
antigen gp70 (15). This antigen is expressed in both CT26 and 4T1
tumor cells (SI Appendix, Fig. S1A) (16), which allowed us to test
LADD-AH1 efficacy in BALB/c mice bearing these tumors. A
single i.v. injection of LADD-AH1 induced complete CT26 tumor
rejection in six of eight mice (Fig. 1A); however, no reduction in
tumor growth was observed with LADD treatment. Notably, i.v.
injection of adenovirus-expressing AH1 (Ad-AH1) did not control
CT26 tumor growth. Consistently, LADD-AH1 induced robust
peripheral AH1 responses, whereas LADD and Ad-AH1 induced
poor AH1 responses (Fig. 1B). Similarly, LADD-AH1 treatment
inhibited 4T1 tumor growth (Fig. 1C). Tumor growth was not
inhibited in LADD-treated mice, even when combined with PD-1
blockade (Fig. 1C). In contrast, LADD-AH1 combined with α-PD-1
resulted in complete 4T1 tumor eradication (Fig. 1C).
Tumor-specific CD8+ T cells were critical for LADD-AH1
efficacy, as control of CT26 tumor growth was largely lost by
CD8+ T cell depletion (Fig. 1D), which also prevented peripheral
AH1 responses (SI Appendix, Fig. S1B). In contrast, depletion of
CD4+ T cells did not impact LADD-AH1 efficacy (SI Appendix,
Fig. S1C). An adoptive transfer experiment further confirmed this
CD8+ T cell requirement where splenic CD8+ T cells from LADD-
AH1-treated 4T1 tumor-bearing mice completely protected recipients
against 4T1 tumor growth (Fig. 1E).
To test whether this striking antitumor efficacy could be observed
in distinct genetic backgrounds, C57BL/6 mice were implanted with
the human papillomavirus (HPV)16-derived-E7 expressing TC1
tumor, which works as a surrogate for human HPV16 tumors (17).
C57BL/6 mice bearing TC1 tumors were treated with LADD
expressing E7 (LADD-E7) or OVA (LADD-OVA). LADD-E7 but
not LADD-OVA was efficacious in this model (Fig. 1F), consistent
with increased peripheral E7 responses upon LADD-E7 immu-
nization (Fig. 1G). Interestingly, LADD-E7 did not induce de-
tectable E7 responses in naive mice, indicating that the TC1 tumor
primed tumor-specific immunity (Fig. 1G). In contrast, the Lm-
specific listeriolysin O (LLO) responses were comparable in
LADD-E7-treated tumor-bearing and naive mice (Fig. 1G). Of
note, s.c. injection of E7 SLP formulated with AddaVax failed to
control TC1 tumor growth (Fig. 1H), which is consistent with poor
induction of E7 responses (SI Appendix, Fig. S1D). In line with our
observations in BALB/c tumor models, CD8+ T cell but not NK cell
depletion prevented TC1 tumor control by LADD-E7 (SI Appendix,
Fig. S1E). Together, these data demonstrated that LADD-induced
antitumor efficacy requires expression of a relevant tumor antigen
from LADD and CD8+ T cells are essential for LADD-Ag potency.
LADD-Ag Immunotherapy Induces Splenic Tumor-Specific CD8+
Effector T Cells. To determine whether Ag expression by LADD
affected the cytokine profile, we measured serum cytokines induced
by LADD and LADD-AH1 in CT26 tumor-bearing mice. At
6-h postinjection, LADD and LADD-AH1 induced comparable
proinflammatory cytokines including MCP-1, IL-12p70 and IFNγ,
demonstrating that Ag expression does not alter cytokines induction
(SI Appendix, Fig. S2A). To assess possible functional differences,
we performed RNA-Seq analysis of peripheral CD8+ T cells purified
from CT26 tumor-bearing mice that were treated with LADD or
LADD-AH1. Principal component analysis indicated that peripheral
CD8+ T cells from HBSS, LADD, or LADD-AH1–treated mice
exhibited distinct transcriptional features (SI Appendix, Fig. S2B).
Remarkably, peripheral CD8+ T cells from LADD-AH1–treated
mice exhibited increased expression of genes related to
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Fig. 1. LADD-Ag administration inhibits growth of multiple tumor models in a CD8+ T cell-dependent manner. (A) S.c. growth of 2 × 105 CT26 in BALB/c mice (n = 8)
i.v. injected with HBSS, 1 × 106 cfu LADD, LADD-AH1, or 1 × 107 CFU Ad-AH1 on day 7. (B) Peripheral blood mononuclear cell (PBMC) IFNγ ELISpot in A with AH1
peptide stimulation was performed on day 14. (C) S.c. growth of 1 × 105 4T1 in BALB/c mice (n = 8) treated with HBSS, LADD, or LADD-AH1 on Day 7. On Days 10 and
17, 100 μg α-PD1 was administered i.p. (D) S.c. growth of 2 × 105 CT26 tumor in BALB/c mice (n = 8) treated with HBSS or LADD-AH1 on day 7. On days 6 and 8, 200 μg
control IgG or α-CD8 was administered i.p. (E) S.c. growth of 5 × 105 4T1 tumor in BALB/c mice (n = 5) which received splenic CD8+ T cells of LADD-AH1 treated or
control 4T1 tumor-bearing mice. (F) S.c. growth of 2 × 105 TC1 tumor in C57/BL6 mice (n = 8) i.v. injected with HBSS, LADD, LADD-OVA, or LADD-E7 on day 7. (G) PBMC
IFNγ ELISpot in F were performed on day 14 with E7 or LLO peptide stimulation. (H) S.c. growth of 2 × 105 TC1 tumor in C57BL/6 mice (n = 8) i.v. injected with HBSS,
LADD-E7, or s.c. injected with 100 μg E7 SLP formulated with AddaVax on day 7. Tumor volumes ±SEM are shown. Numbers of tumor-free mice are indicated in the
figures. In scatter plots, each circle represents one mouse. A, C–F, and H were analyzed by two-way analysis of variance (ANOVA), and B and G were analyzed by
Mann–Whitney U tests. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. Results are representative of at least two independent experiments.
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T cell activation and cytotoxicity signatures, including a substantial
increase in expression of Tbx21, Ifng, Gzmb, Cx3cr1, and Klrg1, rel-
ative to HBSS and LADD treatment (Fig. 2A and SI Appendix,
Table S1). The magnitude of the peripheral AH1-specific CD8+
T cell population also increased dramatically after LADD-AH1
treatment relative to LADD (Fig. 2B). This T cell population
largely displayed a short-lived effector phenotype, characterized
by CD44+CD62L−KLRG1+, consistent with RNA-Seq analysis
(Fig. 2 C and D). While CD44+CD62L− CD8+ T cells trended
higher with LADD treatment relative to HBSS control mice,
this difference was not significant (Fig. 2C). Notably, most of
AH1-specific CD8+ T cells induced by LADD-AH1 were
KLRG1+CD62L−CX3CR1
+CD44+ (SI Appendix, Fig. S2 C–F).
Recent results from two clinical trials highlight the potential of
targeting tumor-specific neoantigens with a therapeutic vaccine
(18, 19). To test whether LADD can elicit neoantigen-specific
CD8+ T cells, we constructed an LADD strain expressing MC38
neoepitopes Adpgk and Reps1 (LADD-Neo) (20). Robust
Adpgk+ CD8+ T cells were detected by tetramer staining in
MC38 tumor-bearing mice treated with LADD-Neo (SI Appen-
dix, Fig. S3 A and B). Significantly, most of the LADD-Neo-
induced Adpgk+ CD8+ T cells were also KLRG1+(SI Appen-
dix, Fig. S3B). LADD-Neo induced significant responses against
the Adpgk neoepitope but did not cross-react against its native
sequence, and LADD-Neo induced higher Adpgk responses in
tumor-bearing mice than in naive mice (SI Appendix, Fig. S3C).
To identify locations of tumor-specific CD8+ T cell priming,
immune responses in tumor draining lymph nodes (TDLN) and
spleen were measured 4 d after LADD-AH1 treatment. TDLN
cells from LADD-AH1–treated mice exhibited enhanced AH1
responses relative to those from HBSS or LADD treatment (Fig.
2E). Additionally, AH1 responses were observed in tumor-
bearing but not naive mice, indicating that implanted CT26
cells primed AH1-specific responses (Fig. 2E). The splenic AH1
CD8+ T cell response induced by LADD-AH1 was significantly
higher than the response measured in the TDLN, which we
confirmed by AH1 tetramer analysis (Fig. 2 E and F). These
results indicated that AH1-specific CD8+ T cells localized pref-
erentially to the spleen and did not reside in the TDLN, likely due
to a lack of CD62L expression (SI Appendix, Fig. S2D). Consistent
with their predominant splenic localization, LADD-AH1-
induced splenic CD8+ T cells displayed increased Ki67, a pro-
liferation marker (Fig. 2G). Furthermore, splenic AH1+CD8+
T cells induced by LADD-AH1 in CT26 tumor-bearing mice
produced IFNγ in response to CT26 as well as 4T1 cells stim-
ulation ex vivo (Fig. 2H and SI Appendix, Fig. S4 A and B).
This was not surprising as both CT26 and 4T1 express Gp70 (SI
Appendix, Fig. S1A). However, LADD-AH1 treatment failed to
induce responses against CT26 neoepitopes whose vaccination
were reported to reject CT26 tumor (21) (SI Appendix, Fig. S4C).
However, these data do not exclude the possibility of epitope
spreading upon LADD-Ag to unknown CT26 antigens.
Notably, splenic AH1+KLRG1+ CD8+ T cells were strongly
induced by LADD-AH1 treatment, whereas these cells existed at
low levels in LADD and HBSS groups (Fig. 2I). To explore
whether AH1+KLRG1+ CD8+ T cells were differentiated and
expanded from AH1+KLRG1− CD8+ T cells primed by tumor
implantation, splenic CD45.1+CD8+ T cells from tumor-bearing
mice were adoptively transferred into naive CD45.2+ recipients.
Indeed, donor AH1+KLRG1− CD8+ T cells expanded and differ-
entiated into AH1+KLRG1+ CD8+ T cells upon LADD-AH1 but
not LADD immunization (Fig. 2J and SI Appendix, Fig. S4D).
While an increase in KLRG1 expression and proliferation of donor
CD8+ T cells was observed in recipients upon LADD immuniza-
tion, this strain did not expand AH1+ CD8+ T cells, demonstrating
a requirement for LADD-mediated expression of the cognate tu-
mor Ag (SI Appendix, Fig. S4D). Recipient CD45.2+AH1+CD8+
T cells were detectable but at a low frequency following LADD-
AH1 injection (Fig. 2J), consistent with a weak tumor-specific
response in naive animals (Fig. 1G and SI Appendix, Fig. S3C).
LADD-Induced Functional Tumor-Specific CD8+ T Cells Infiltrate into
Tumors. TME modification to promote tumor cell destruction in
malignancies is an essential step for effective immunotherapy.
We measured the magnitude and interrogated the phenotype of
CD8+ T cells infiltrating CT26 tumors to characterize how LADD
impacts the TME, and to determine whether LADD-induced tumor-
specific CD8+ T cells affected the TME profile. Immunohistochem-
istry (IHC) and flow cytometry analysis 4 d after LADD-AH1
treatment showed a marked increase in the frequency of tumor
A
F G H I J
B C D E
Fig. 2. LADD-AH1 immunotherapy induces splenic AH1-specific CD8+ effector T cells. (A–I) CT26 tumor-bearing BALB/c mice (n = 8) were i.v. injected with
HBSS, LADD, or LADD-AH1 on day 7. (A–D) On day 14, (A) RNA-Seq analysis of peripheral CD8+ T cells purified from a pool of eight mice per group. Heat map
of selected genes from the core signature. Log2 of gene expression values (TPM, transcripts per million) are colored from blue to red. Frequencies of (B) AH1
tetramer+, (C) CD44+CD62L−, and (D) KLRG1+ of peripheral CD8+ T cells were measured by flow staining. (E–I) On Day 11, (E) TDLN and spleen IFNγ ELISpot
were performed with AH1 peptide stimulation. Naive mice served as control. (F and G) Frequency of (F) AH1 tetramer+ and (G) Ki67+ of TDLN or splenic CD8+
T cells. (H) IFNγ production by splenic CD8+ T cells were tested with CT26 cells stimulation ex vivo. (I) Frequency of AH1+KLRG1− and AH1+KLRG1+ of splenic
CD8+ T cells. (J) Adoptive transfer of purified CD45.1+ CD8+ donor T cells from CT26 tumor-bearing mice into CD45.2+ mice (recipients, n = 8). Mice were
immunized with HBSS, LADD-AH1, and LADD one day later. Seven days postimmunization, frequency of AH1 tetramer+ of donor and recipient CD8+ T cells. B–
D were analyzed by one-way ANOVA with Tukey’s multiple comparisons test, E–J were analyzed by Mann–Whitney U tests. *P < 0.05, **P < 0.01, ***P <
0.001, and ****P < 0.0001. Results are representative of at least two independent experiments.
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infiltrating CD8+ T cells (Fig. 3 A and B and SI Appendix, Fig. S5A).
Interestingly, PD-1 expression on CD8+ T cells decreased with both
LADD and LADD-AH1 treatment (Fig. 3C). Remarkably, treat-
ment with LADD-AH1 but not LADD led to a massive increase in
IFNγ-producing AH1-specific CD8+ T cells in the TME (Fig. 3
D and E). Furthermore, the principal increased population of
AH1+ CD8+ T cells in the TME induced by LADD-AH1
treatment were AH1+KLRG1+ CD8+ effector cells (Fig. 3F and
SI Appendix, Fig. S5B). RNA-Seq analysis revealed distinct gene
signatures between the AH1+KLRG1− and AH1+KLRG1+ CD8+
T cell populations in LADD-AH1–treated tumors (Fig. 3G).
AH1+KLRG1+CD8+ T cells expressed higher levels of Gzma, Ifng,
and Ccl5, but lower levels of Pdcd1, Lag3, Ctla4, and Socs3 com-
pared with AH1+KLRG1−CD8+ T cells (Fig. 3G and SI Appendix,
Table S2). Flow analysis confirmed that AH1+KLRG1+CD8+
T cells expressed lower levels of PD-1, LAG3 (Fig. 3H and SI
Appendix, Fig. S5 C and D) and produced higher levels of IFNγ
(Fig. 3I), indicating that LADD-AH1 induced a functional
AH1+KLRG1+ CD8+ T cell population that was not exhausted.
To test AH1+KLRG1+ CD8+ T cells primed in the spleen that
subsequently trafficked into the TME, we used the sphingosine
1-phosphate analog FTY720, a drug that inhibits egress of lym-
phocytes including CD8+ T cells from secondary lymphoid or-
gans (22). While similar levels of AH1+CD8+ T cells were
present in the TME of HBSS- or FTY720-treated mice, tumor-
infiltrating AH1+CD8+ T cells were reduced in LADD-AH1–
treated mice that also received FTY720 (Fig. 3J). Together,
these results indicate that while the LADD itself induced
changes in the TME, only LADD-AH1 induced IFNγ-producing
AH1+KLRG1+ CD8+ effector T cells that traffic to tumors.
TME Remodeling Is Dependent on LADD-Induced Tumor-Specific CD8+
T Cells. The TME is highly immunosuppressive partially due to
inhibitory cell populations, including Tregs, MDSCs, and TAMs.
We next characterized these populations in the TME after
LADD treatment. LADD-AH1 treatment decreased tumor-
infiltrating Treg frequency (Fig. 4A), which when combined
with the high magnitude of CD8+ effector T cells in the TME
(Fig. 3 A and B) dramatically increased the ratio of CD8+ T cells
to Tregs (CD8/Treg) (P < 0.0001; Fig. 4B). Interestingly, LADD
treatment also decreased Treg frequency (Fig. 4A) and increased
CD8/Treg ratio (P < 0.05) (Fig. 4B), consistent with TME
modification by the LADD vector itself.
Interestingly, treatment with LADD-AH1 but not LADD in-
duced iNOS production and prevented CD206 expression by
TAMs, and this phenotype was completely abrogated by CD8+
T cell depletion (Fig. 4 C and D). These results indicate that the
tumoral M2 to M1 macrophage shift depended on LADD-AH1–
induced CD8+ T cells. TAM reprogramming following Lm
phagocytosis has been previously reported (23). This is unlikely
given that LADD-AH1 was enriched in the spleen and liver, but
not the CT26 tumors of mice (Fig. 4E), and LADD was unable
to induce TAM reprogramming. LADD-AH1 was cleared 7 d
postinjection, when CT26 tumors started collapsing (SI Ap-
pendix, Fig. S6A). The discrepancy between our observation and
previous reports may be due to difference in models.
To test whether CD8+ T cells could directly mediate TAMs
repolarization, we cocultured splenic CD8+ T cells with an un-
treated CT26 tumor suspension ex vivo. Indeed, the presence of
LADD-AH1–induced AH1+CD8+ effector T cells increased
iNOS production and decreased CD206 expression in TAMs (Fig.
4 F and G). Increased iNOS production was blocked by α-IFNγ,
while CD206 expression was unaffected (Fig. 4 F and G). These
data suggested that IFNγ produced by AH1+CD8+ T cells is es-
sential for iNOS production but not CD206 down-regulation.
To further test the role of TAMs in vivo, we employed anti-
CSF-1R and anti-CCL2 antibodies to prevent TAMs recruitment
into the tumor (24, 25). Anti-CSF-1R/CCL2 treatment delayed
CT26 tumor growth, which might be a result of M2 removal from
the TME (SI Appendix, Fig. S6B). Furthermore, LADD-AH1
still controlled CT26 tumor growth following anti-CSF-1R/
CCL2 treatment although we observed a tendency toward in-
creased tumor burden in some LADD-AH1–treated mice. These
data suggest that TAMs are not essential for LADD-Ag efficacy.
We further examined the TME cytokine and chemokine pro-
file by luminex. Consistent with TAMs repolarization, in-
flammatory cytokines including IFNγ and TNFα dramatically
increased in the TME upon LADD-AH1 immunization (Fig. 4 H
and I), which depended on LADD-AH1–induced CD8+ T cells.
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Fig. 3. Functional AH1-specific CD8+ effector T cells induced by LADD-AH1 infiltrated CT26 tumors. CT26 tumor-bearing mice (n = 5–10) were immunized
with HBSS, LADD-AH1, or LADD on day 7. (A) IHC staining of CD8+ T cells infiltration of CT26 tumor on day 11. (Scale bars: 100 μm.) (B) Frequencies of CD8+
T cells in CD45+ population of the TME. (C) PD-1 expression on tumor-infiltrating CD8+ T cells by calculation of mean fluorescence intensity (MFI). (D) Fre-
quency of AH1 tetramer+ of CD8+ T cells. (E) Intracellular IFNγ production by tumor-infiltrating CD8+ T cells were tested with AH1 peptide stimulation ex vivo.
(F) Frequency of AH1+KLRG1− and AH1+KLRG1+ of CD8+ T cells. (G–I) Comparison of AH1+KLRG1− and AH1+KLRG1+ tumor-infiltrating CD8+ T cells from
LADD-AH1–treated mice, (G) RNA-Seq analysis. Heat map of selected genes out of core signature. Log2TPM are colored from blue to red. (H) PD-1 expression
(MFI). (I) Intracellular IFNγ production. (J) Frequency of AH1+KLRG1− and AH1+KLRG1+ of CD8+ T cells in TME with or without FTY720 treatment. In scatter
plots, each circle represents one mouse. B–F and Jwere analyzed by one-way ANOVA with Tukey’s multiple comparisons test. H and Iwere analyzed by Mann–
Whitney U tests. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
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Notably, LADD treatment also increased chemokines such as
MCP3 and RANTES in the TME (SI Appendix, Fig. S6C).
LADD-Neo–induced Adpgk+ CD8+ T cells also infiltrated
MC38 tumors (SI Appendix, Fig. S7 A and B), and resulted in an
increased CD8/Treg ratio and iNOS production by TAMs (SI
Appendix, Fig. S7 C and D). Together, these results show that
LADD-Ag–induced IFNγ producing tumor-specific CD8+ T cells
infiltrate tumors, remodel the TME, and thus control tumor
growth (SI Appendix, Fig. S8).
LADD-Ag Induces Effector Memory T Cells That Protect Against Tumor
Rechallenge. We next characterized the level and function of
tumor-specific CD8+ T cells from CT26 tumor-bearing mice that
were cured by LADD-AH1 treatment (survivors). Six weeks after
LADD-AH1 treatment, a high percentage of AH1+CD8+ T cells
persisted in survivors (Fig. 5A). These AH1+CD8+ T cells mostly
expressed KLRG1 and T-bet but not Ki67 (Fig. 5 B–D), sug-
gesting they were effector memory T cells. Furthermore, the
AH1+KLRGhiT-bethi CD8+ T cell population that persisted in
the periphery were functional and completely protected mice
against CT26 tumor rechallenge (Fig. 5E and SI Appendix, Fig.
S9A). Notably, CD8+ T cell depletion only partially impaired this
ability (Fig. 5E). Significant levels of NK cells, iNOS-producing
TAMs and AH1-specific CD8+ T cells were detected in the TME
of survivors 3 d after rechallenge with a very high dose of tumor
cells (4 × 106) (SI Appendix, Fig. S9 B–D). Remarkably, about 60%
of tumor-infiltrating CD8+ T cells were AH1-specific in these mice
(SI Appendix, Fig. S9E). Together, these data illustrate that LADD-
AH1 treatment induced a large population of highly functional
tumor-specific CD8+ T cells that both repolarize the TME and elicit
effective primary and secondary antitumor responses.
Discussion
The scientific rationale for the clinical advancement of Lm-based
immunotherapies is in part due to observations in the mouse
infection model where a single immunization with sublethal
doses of WT Lm confers protection against lethal WT Lm
challenge (26). Protection is entirely dependent upon potent
bacterial-specific T cell immunity. While our previous investi-
gations have demonstrated the antitumor potency of LADD-Ag
(14), here we describe the immunologic correlates of this effi-
cacy. We show that while LADD itself induced proinflammatory
cytokines and some TME changes including decreased PD-1
expression on tumor-infiltrating CD8+ T cells and an increased
CD8/Treg ratio, these changes were not sufficient to confer an-
titumor efficacy. Instead, LADD-Ag primed high numbers of T-
bet+KLRG1hiPD-1loCD62L− tumor-specific CD8+ T cells in the
spleen. This T cell population infiltrated the tumor, resulting in a
TME profile measured at the transcriptional, protein, and cell
population levels that differed significantly from LADD.
The lack of antitumor efficacy by LADD or LADD expressing
an irrelevant antigen highlights the importance of expression of
cognate tumor antigens. The magnitude of peripheral tumor-
specific responses increased in tumor-bearing mice relative to
naive animals upon LADD-Ag immunization. This result demon-
strated that a robust tumor-specific immune response required tumor
implantation and Ag presentation/priming, along with LADD-Ag
immunization. Indeed, our adoptive transfer experiment showed that
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Fig. 4. Remodeling of TME is dependent on LADD-AH1–induced AH1-specific
CD8+ T cells. (A–D) CT26 tumor-bearing mice (n = 8–10) were immunized with
HBSS, LADD-AH1, or LADD on day 7. Mice were treated with α-CD8 on day 6 and 8
when indicated. On day 11 in the TME. (A) Frequency of Treg in CD45+ population.
(B) CD8/Treg ratio. (C) iNOS production by TAMs. (D) CD206 expression by TAMs.
(E) CT26 tumor-bearingmice (n= 4) were i.v. injectedwith LADD-AH1 on day 7. Lm
per spleen, liver, or tumor were determined at 24 h, 72 h, and 7 d later. (F and G)
Purified splenic CD8+ T cells from LADD-AH1–treated or control CT26 tumor-
bearing mice were cocultured with an untreated CT26 tumor suspension with or
without 10 μg/mL IFNγ for 24 h. (F) iNOS production by TAMs. (G) CD206 expres-
sion by TAMs. (H and I) Conditions asA–D. (H) IFNγ level (picograms permilliliter) (I)
TNFα level (picograms per milliliter) in supernatants of tumor. In scatter plots, each
circle represents one mouse. All panels were analyzed by one-way ANOVA with
Tukey’s multiple comparisons test. *P < 0.05, **P< 0.01, ***P < 0.001, and ****P <
0.0001. Results are representative of at least two independent experiments.
A B C D E
Fig. 5. LADD-AH1 induces memory effector CD8+ T cells that protect survivors from CT26 rechallenge. Survivors and naive mice were reinoculated with CT26 in their
left thoracic flanks. (A–D) Before reinoculation, (A) frequency of peripheral AH1 tetramer+ of CD8+ T cells, (B–D) Representative staining of AH1 tetramer and (B)
KLRG1, (C) Ki67, or (D) T-bet of peripheral CD8+ T cells in survivors. (E) S.c. growth of 5 × 105 CT26 in naive mice (n = 5) and survivors treated with control IgG or α-CD8.
Tumor volumes ±SEM are shown. In scatter plots, each circle represents one mouse. FACS plots show representative analysis for one mouse per group. Awas analyzed
by Mann–Whitney U tests. E was analyzed by two-way ANOVA. *P < 0.05 and ****P < 0.0001. Results are representative of at least two independent experiments.
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tumor implantation itself primed AH1+CD8+ T cells, which could be
amplified by LADD-AH1 immunization (Fig. 2J). These data are
consistent with previous observations that AH1 is a weak agonist for
its cognate T cell receptor [KD = 5.7 μM, t1/2 (s) = 2] (27) and the
dominant target for CT26-specific CTL responses (15). In contrast,
LLO responses were comparable in tumor-bearing and naive mice
because LLO is strongly immunogenic and is presented to CD4+ and
CD8+ T cells at pM and nM levels (28).
Tumor growth can proceed unabated despite abundant tumor-
specific T cells in the TME (Fig. 3D), indicating that these T cells
are dysfunctional. Rapid induction of dysfunctional tumor-specific
T cells occurs through continuous antigen encounter in an immu-
nosuppressive TME (2). It is well-established that microbial infection
can induce protective pathogen-specific T cells (9). In this study, we
utilized attenuated Lm to generate functional cytotoxic CD8+ T ef-
fector cells that overcome the immunosuppressive TME and promote
tumor rejection. LADD-Ag delivers antigens into the cytoplasm of
infected cells such as dendritic cells (DCs) for processing and pre-
sentation on MHC molecules, which provides a sustained source of
tumor antigen and innate immune stimulation. In this context, tumor-
specific T cells were amplified where tumor antigen was presented on
activated DCs. The phenotypic CX3CR1+CD62L−KLRG1+PD-1lo
profile of LADD-Ag–induced tumor-specific CD8+ T cells resembled
that of cytolytic pathogen-specific effector cells (11, 29). The phe-
notype of LADD-Ag induced CD8+ T cells allowed us to distinguish
them from resident tumor-specific T cells. Transcriptome analysis
further revealed distinct functional signatures of tumor-specific
T cells resulting from LADD-based immunotherapy. Tumor-
specific T cells induced in the inflammatory context were less
exhausted, produced IFNγ, controlled tumor growth, and estab-
lished long-term memory.
Both antigens and adjuvants remain the focus of questions
surrounding the optimal design of cancer vaccines. Viral antigens
and neoantigens are considered ideal targets because of the lack
of central tolerance (8). The preclinical potency of LADD ex-
pressing the viral antigens AH1 and E7 highlights the therapeutic
potential of targeting viral antigens. Indeed, numerous therapeutic
vaccination strategies against E7 have been developed for the
treatment of cervical cancer and HPV-associated disease (30).
Moreover, the strength of vaccine-induced T cell immune responses
correlates with the clinical response (31). Interestingly, human en-
dogenous retroviral antigens are emerging as novel immunotherapy
targets (32). Notably, gp70 levels are strikingly high in murine tumor
cell lines (16), and the gp70-derived AH1 epitope is highly immu-
nodominant, which could explain both LADD-AH1 antitumor ef-
ficacy and the lack of epitope spreading against other known CT26
antigens. In addition to viral antigens, LADD-Neo can elicit
neoantigen-specific CD8+ T cells and TME changes in a preclinical
mouse model, which provides rationale for LADD treatment tar-
geting neoantigens. We recently initiated a clinical trial targeting
neoantigens in patients with microsatellite stable colorectal cancer
(NCT03189030). The possibility of developing antigen-loss variants
is limited by designing LADD expressing multiple neoepitopes that
can activate T cells against a variety of antigens. Many platforms are
currently used for cancer vaccine development. Compared with the
other platforms we tested, LADD appears to be an optimal vehicle
for active immunotherapy in mice. Further experiments are re-
quired to fully understand its superior activity in preclinical models.
Materials and Methods
LADD-Ag strains, cells, antibodies, and other reagents used in this study are
described in SI Appendix. Detailed information on immunization, in vivo
tumor experiments, antibody staining and flow cytometry analysis, IFNγ
ELISpot and ICS assays, isolation of CD8+ T cells and RNA-Seq, adoptive
transfer of CD8+ T cells, luminex, IHC staining and histological analysis of
CD8 infiltration, LADD biodistribution studies, and statistics can be found in
SI Appendix. This study was performed according to protocols approved by
the Institutional Animal Use Committee of Aduro Biotech.
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